Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, will advance and accelerate CYDY’s initiatives in seeking non-dilutive licensing opportunities in cancer and immunology.
“We are honored to have Dr. Pestell serve as our Vice Chairman,” CytoDyn President and Chief Executive Officer Nader Pourhassan stated in the news release. “He is a world renowned cancer expert who has published over 500 papers. We envision the role of our Vice Chairman to serve as an ambassador capable of delivering our message of the potential for our platform drug leronlimab (“PRO 140”) worldwide. It just makes sense to elevate Dr. Pestell to this position, as we expect future results from our program to bring our technology into the spotlight. Dr. Pestell has the credibility on the world stage to represent the technology to other drug companies, potential collaborators, licensees and key opinion leaders. We also recognize his track record of success in overseeing cancer clinical trials for more than 13 years as the Director of two NCI -designated cancer centers. His expertise using CCR5 inhibitors in preclinical studies and the relationships he built while maintaining his commitment to excellence facilitated the approval from the FDA to proceed with our cancer trial. With his broad leadership experience and CCR5 expertise, CytoDyn has strengthened the development of leronlimab as a novel therapeutic for cancer metastasis.”
To view the full press release, visit http://nnw.fm/0JlPw
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The company plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first half of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and initiated a clinical trial with leronlimab in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.